HCPCS Level II code C9067 denotes Gallium Ga-68 DOTATOC, a radiopharmaceutical diagnostic agent (0.01 mCi) used in PET imaging to detect somatostatin receptor–positive tumors such as neuroendocrine tumors. Nationally, availability and coding for Ga-68–based somatostatin receptor imaging matter because these agents improve diagnostic sensitivity and can affect care pathways, imaging utilization, and reimbursement for advanced molecular imaging.

Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context and typical sites of service, plus benchmarks and policy-relevant details where available. The publication outlines common billing considerations, typical modifiers used with radiopharmaceutical codes, and payer coverage patterns when available.

This summary equips clinical administrators, coding specialists, and policy analysts with background on the code’s clinical purpose, the service environment in which it is delivered, and the payer landscape to expect. Data not available in the input is noted where relevant.